Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].

Bulletin du cancer - 1 Sept 2018

Herviou Laurie, Cavalli Giacomo, Moreaux Jerome

Abstract excerpt

Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that functions as the catalytic subunit of the polycomb repressive complex 2 (PRC2). PRC2 represses gene transcription through tri-methylation of lysine 27 of histone 3 (H3K27me3) by its catalytic subunit EZH2. EZH2 is also involved in normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B-Lymphocytes
Share to Cell Differentiation
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Molecular Targeted Therapy

Share to Multiple Myeloma

Share to Neoplasm Proteins

Share to Precision Medicine

Source

Identifiers

PMID: 30041976
DOI: 10.1016/j.bulcan.2018.06.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].PMID 30041976Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaSemantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

The epigenetic role of EZH2 in acute myeloid leukemiaSemantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetSemantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.